Solubility Enhancement of Budesonide and Statistical Optimization of Coating Variables for Targeted Drug Delivery

Table 15

In vitro drug release study of HB2 after stability.

Time (hours)	% Drug release (mean ± S.D.)
	0 month	1 month	2 months	3 months
1	2.54±0.79	2.93±0.83	3.14±0.45	3.45±1.09
2	6.75±1.49	6.09±0.30	5.92±0.91	6.12±1.21
3	6.80±1.49	6.09±0.30	5.92±0.91	6.12±1.21
4	6.80±1.49	6.09±0.30	5.92±0.91	6.12±1.21
5	20.82±2.03	21.18±0.24	22.41±1.78	22.89±1.98
6	35.14±2.50	35.83±0.27	37.77±2.10	36.39±1.91
7	51.01±0.95	51.83±0.30	52.49±0.56	50.42±0.71
8	79.33±0.72	80.61±0.18	81.66±1.11	82.48±1.39
9	94.15±0.40	94.65±1.08	93.90±0.90	92.60±0.97
10	101.67±1.97	102.35±0.42	102.71±2.22	102.11±2.56